RBOT
Vicarious Surgical Inc.
Medical - Devices
Market Cap$3M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RBOT vs SSYS
Revenue, margins, valuation, and 5-year total return — side by side.
SSYS
Stratasys Ltd.
Computer Hardware
Market Cap$707M
5Y Perf.-34.2%
RBOT vs SSYS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RBOT | SSYS |
|---|---|---|
| Industry | Medical - Devices | Computer Hardware |
| Market Cap | $3M | $707M |
| Revenue (TTM) | $0.00 | $551M |
| Net Income (TTM) | $-42M | $-104M |
| Gross Margin | — | 43.6% |
| Operating Margin | — | -11.7% |
| Forward P/E | — | 69.8x |
| Total Debt | $8M | $27M |
| Cash & Equiv. | $3M | $95M |
RBOT vs SSYS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RBOT
SSYS
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Vicarious Surgical … (RBOT) | 100 | 0.2 | -99.8% |
| Stratasys Ltd. (SSYS) | 100 | 65.8 | -34.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RBOT vs SSYS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SSYS leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Vicarious Surgical Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
RBOT
Vicarious Surgical Inc.
The Growth Leader
RBOT is the clearest fit if your priority is growth and quality.
- 31.5% revenue growth vs SSYS's -3.7%
- 5.0% margin vs SSYS's -18.9%
Best for: growth and quality
SSYS
Stratasys Ltd.
The Income Pick
SSYS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.79
- Rev growth -3.7%, EPS growth 24.7%, 3Y rev CAGR -5.4%
- -60.6% 10Y total return vs RBOT's -99.8%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RBOT | 31.5% revenue growth vs SSYS's -3.7% |
| Quality / Margins | RBOT | 5.0% margin vs SSYS's -18.9% |
| Stability / Safety | SSYS | Beta 1.79 vs RBOT's 1.92, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SSYS | -15.6% vs RBOT's -94.1% |
| Efficiency (ROA) | SSYS | -9.6% ROA vs RBOT's -164.5%, ROIC -5.8% vs -116.2% |
RBOT vs SSYS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
RBOT vs SSYS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSSYSLAGGINGRBOT
RBOTVicarious Surgical In…
0leads
SSYSStratasys Ltd.
4leads
6 Total Categories
CATEGORYLEADERvs RBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SSYS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SSYS7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
SSYS6/6
Risk & VolatilityBeta, volatility, and downside exposure
SSYS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SSYS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SSYS and RBOT operate at a comparable scale, with $551M and $0 in trailing revenue.
| Metric | RBOTVicarious Surgica… | SSYSStratasys Ltd. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $551M |
| EBITDAEarnings before interest/tax | -$42M | -$32M |
| Net IncomeAfter-tax profit | -$42M | -$104M |
| Free Cash FlowCash after capex | -$40M | -$8M |
| Gross MarginGross profit ÷ Revenue | — | +43.6% |
| Operating MarginEBIT ÷ Revenue | — | -11.7% |
| Net MarginNet income ÷ Revenue | — | -18.9% |
| FCF MarginFCF ÷ Revenue | — | -1.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +58.1% | +62.7% |
SSYS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RBOT and SSYS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RBOTVicarious Surgica… | SSYSStratasys Ltd. |
|---|---|---|
| Market CapShares × price | $3M | $707M |
| Enterprise ValueMkt cap + debt − cash | $8M | $639M |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | -6.41x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 69.79x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.28x |
| Price / BookPrice ÷ Book value/share | 0.30x | 0.79x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RBOT and SSYS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SSYS leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
SSYS delivers a -12.3% return on equity — every $100 of shareholder capital generates $-12 in annual profit, vs $-3 for RBOT. SSYS carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), SSYS scores 6/9 vs RBOT's 1/9, reflecting solid financial health.
| Metric | RBOTVicarious Surgica… | SSYSStratasys Ltd. |
|---|---|---|
| ROE (TTM)Return on equity | -3.3% | -12.3% |
| ROA (TTM)Return on assets | -164.5% | -9.6% |
| ROICReturn on invested capital | -116.2% | -5.8% |
| ROCEReturn on capital employed | -134.6% | -6.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 6 |
| Debt / EquityFinancial leverage | 0.79x | 0.03x |
| Net DebtTotal debt minus cash | $5M | -$68M |
| Cash & Equiv.Liquid assets | $3M | $95M |
| Total DebtShort + long-term debt | $8M | $27M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
SSYS leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
SSYS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SSYS five years ago would be worth $4,090 today (with dividends reinvested), compared to $16 for RBOT. Over the past 12 months, SSYS leads with a -15.6% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors SSYS at -17.0% vs RBOT's -80.2% — a key indicator of consistent wealth creation.
| Metric | RBOTVicarious Surgica… | SSYSStratasys Ltd. |
|---|---|---|
| YTD ReturnYear-to-date | -80.6% | -9.0% |
| 1-Year ReturnPast 12 months | -94.1% | -15.6% |
| 3-Year ReturnCumulative with dividends | -99.2% | -42.9% |
| 5-Year ReturnCumulative with dividends | -99.8% | -59.1% |
| 10-Year ReturnCumulative with dividends | -99.8% | -60.6% |
| CAGR (3Y)Annualised 3-year return | -80.2% | -17.0% |
SSYS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SSYS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SSYS is the less volatile stock with a 1.79 beta — it tends to amplify market swings less than RBOT's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SSYS currently trades 64.0% from its 52-week high vs RBOT's 3.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RBOTVicarious Surgica… | SSYSStratasys Ltd. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.92x | 1.79x |
| 52-Week HighHighest price in past year | $13.75 | $12.81 |
| 52-Week LowLowest price in past year | $0.35 | $7.34 |
| % of 52W HighCurrent price vs 52-week peak | +3.6% | +64.0% |
| RSI (14)Momentum oscillator 0–100 | 30.0 | 64.8 |
| Avg Volume (50D)Average daily shares traded | 24K | 818K |
SSYS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | RBOTVicarious Surgica… | SSYSStratasys Ltd. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $13.50 |
| # AnalystsCovering analysts | — | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SSYS leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallStratasys Ltd. (SSYS)Leads 4 of 6 categories
Loading custom metrics...
RBOT vs SSYS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RBOT or SSYS a better buy right now?
Analysts rate Stratasys Ltd.
(SSYS) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RBOT or SSYS?
Over the past 5 years, Stratasys Ltd.
(SSYS) delivered a total return of -59. 1%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: SSYS returned -60. 6% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RBOT or SSYS?
By beta (market sensitivity over 5 years), Stratasys Ltd.
(SSYS) is the lower-risk stock at 1. 79β versus Vicarious Surgical Inc. 's 1. 92β — meaning RBOT is approximately 7% more volatile than SSYS relative to the S&P 500. On balance sheet safety, Stratasys Ltd. (SSYS) carries a lower debt/equity ratio of 3% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RBOT or SSYS?
On earnings-per-share growth, the picture is similar: Stratasys Ltd.
grew EPS 24. 7% year-over-year, compared to 21. 2% for Vicarious Surgical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RBOT or SSYS?
Vicarious Surgical Inc.
(RBOT) is the more profitable company, earning 0. 0% net margin versus -18. 9% for Stratasys Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RBOT leads at 0. 0% versus -10. 7% for SSYS. At the gross margin level — before operating expenses — SSYS leads at 47. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RBOT or SSYS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RBOT or SSYS better for a retirement portfolio?
For long-horizon retirement investors, Stratasys Ltd.
(SSYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Vicarious Surgical Inc. (RBOT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSYS: -60. 6%, RBOT: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RBOT and SSYS?
These companies operate in different sectors (RBOT (Healthcare) and SSYS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.